Name | 3-(methanesulfonamido)-2-phenyl-N-[(1S)-1-phenylpropyl]quinoline-4-carboxamide |
---|---|
Synonyms |
unii-3u471zvc5k
azd2624 MLE-4901 |
Description | Pavinetant (MLE-4901) is a neurokinin-3 receptor (NK3R) antagonist. |
---|---|
Related Catalog | |
Target |
NK3R[1] |
In Vitro | Pavinetant (AZD2624) is a potent and selective NK3 receptor antagonist which is developed for the treatment of schizophrenia. Pavinetant exhibits an inhibitory effect on microsomal CYP3A4/5 activities with apparent IC50 values of 7.1 and 19.8 μM for midazolam and testosterone assays, respectively. No time-dependent inactivation of CYP3A4/5 activity by Pavinetant is observed. Pavinetant demonstrates weak to no inhibition of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP2D6[1]. |
Kinase Assay | The potential of Pavinetant (AZD2624) to cause time-dependent inhibition of CYP3A activities is evaluated by pre-incubating 10 μM of Pavinetant at 37°C for 0, 3, 10, 20, and 30 min in 0.1 M pH 7.4 phosphate buffer incubation mixture (0.2 mL) containing 2 mg/mL HLM and 1 mM NADPH. Verapamil, tested at 10 μM, is also incubated separately as a positivecontrol. An aliquot of 20 μL is removed from pre-incubation tube at each time point and added to a secondary 5-min incubation(180 μL) containing 15 μM of midazolam and 1 mM of NADPH. The formation of 1′-hydroxymidazolam is used as the marker activity for CYP3A enzymes and analyzed using LC-MS. CYP3A enzyme activities after pre-incubation with Pavinetant arecompared to activities following incubation with vehicle solvent (1% methanol) and without pre-incubation[1]. |
References |
Molecular Formula | C26H25N3O3S |
---|---|
Molecular Weight | 459.56000 |
Exact Mass | 459.16200 |
PSA | 100.03000 |
LogP | 6.88300 |